Fabrizio Maria Anella

Title: Fabrizio Maria Anella: Innovator in SARS-CoV-2 Research

Introduction

Fabrizio Maria Anella is a prominent inventor based in Hong Kong, CN. He has made significant contributions to the field of biotechnology, particularly in the development of methods related to the SARS-CoV-2 virus. His innovative work focuses on the efficient expression and purification of the receptor binding domain (RBD) of the virus, which is crucial for vaccine development.

Latest Patents

Fabrizio holds a patent titled "Efficient expression system of SARS-CoV-2 receptor binding domain (RBD), methods for purification and use thereof." This invention pertains to the production of the RBD of the Spike glycoprotein 1 of SARS-CoV-2 in mammalian cell expression systems. The patent outlines a method for producing a recombinant plasmid containing the coding sequence of the RBD, which is transfected into mammalian cells, such as Expi293. The process results in a high yield of the protein, which is then purified using an N-terminal tag that can be removed by a specific protease. This invention also includes a recombinant expression vector carrying the RBD gene and methods for its purification, as well as strategies for establishing stable cell lines for RBD production. The recombinant protein has potential applications in formulating pharmaceutical compositions, including vaccines for preventing SARS-CoV-2 induced diseases. Fabrizio has 1 patent to his name.

Career Highlights

Fabrizio is currently employed at Betagen Scientific Limited, where he continues to advance his research in biotechnology. His work is instrumental in the ongoing efforts to combat viral diseases through innovative scientific approaches.

Collaborations

Fabrizio collaborates with notable colleagues, including Alan Chang and Clement M Lee, who contribute to his research endeavors and help drive forward the mission of their organization.

Conclusion

Fabrizio Maria Anella is a key figure in the field of biotechnology, particularly in the fight against SARS-CoV-2. His innovative patent and ongoing research efforts highlight his commitment to advancing medical science and improving public health.